银屑病-特应性皮炎重叠表型：免疫失衡机制与临床诊治新视角

doi:10.35541/cjd.20250219

Abstract

Abstract: 【Abstract】 Atopic dermatitis and psoriasis are two chronic inflammatory skin diseases with distinct immune mechanisms, primarily driven by Th2-type inflammation and Th1/Th17 pathways, respectively. However, some patients may simultaneously or sequentially exhibit overlapping phenotypes of atopic dermatitis and psoriasis（psoriasis-atopic dermatitis overlap, PAO）, characterized by the coexistence of scaly erythema and eczematous lesions. Currently, the nomenclature, diagnostic criteria, and pathogenesis of PAO remain unclear, and its incidence is increasing due to the widespread use of targeted therapies. The diagnosis of PAO requires an integrated assessment of clinical features, histopathological findings, and biomarker profiles, while treatment necessitates a balance between immune modulation and individualized strategies. This article summarizes the characteristic manifestations of and genetic-immune interactions involved in PAO based on clinical practice, and explores diagnostic challenges and therapeutic options to address this complex and increasingly prominent clinical issue.

Key words: Dermatitis, atopic, Psoriasis, Eczema, Overlap, Immune mechanism, Molecular targeted therapy

Song Zhiqiang, He Yuanxiong, Chen Anqi. Psoriasis-atopic dermatitis overlap phenotype: immune dysregulation mechanisms and emerging clinical insights[J]. Chinese Journal of Dermatology, 2025, 58(11): 1009-1014.doi:10.35541/cjd.20250219

References ［58］

［1］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［2］	Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis［J］. Nat Rev Dis Primers, 2018,4（1）:1. doi: 10.1038/s41572⁃018⁃0001⁃z.
［3］	Ständer S. Atopic dermatitis［J］. N Engl J Med, 2021, 384（12）: 1136⁃1143. doi: 10.1056/NEJMra2023911.
［4］	Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990⁃2017［J］. Br J Dermatol, 2021,184（2）:304⁃309. doi: 10.1111/bjd.19580.
［5］	Lauffer F, Eyerich K. Eczematized psoriasis ⁃ a frequent but often neglected variant of plaque psoriasis［J］. J Dtsch Dermatol Ges, 2023,21（5）:445⁃453. doi: 10.1111/ddg.14991.
［6］	Kouwenhoven TA, Bronckers I, van de Kerkhof P, et al. Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children［J］. J Eur Acad Dermatol Venereol, 2019,33（2）:e74⁃e76. doi: 10.1111/jdv.15213.
［7］	Noorily AR, Criscito MC, Cohen JM, et al. Psoriasis with eczematous features: a retrospective clinicopathologic study［J］. Am J Dermatopathol, 2021,43（2）:112⁃118. doi: 10.1097/DAD.0000000000001711.
［8］	Dai YX, Tai YH, Chang YT, et al. Bidirectional association between psoriasis and atopic dermatitis: a nationwide population⁃based cohort study［J］. Dermatology, 2021,237（4）:521⁃527. doi: 10.1159/000514581.
［9］	Han JH, Bang CH, Han K, et al. The risk of psoriasis in patients with allergic diseases: a nationwide population⁃based cohort study［J］. Allergy Asthma Immunol Res, 2021,13（4）:638⁃645. doi: 10.4168/aair.2021.13.4.638.
［10］	Lee HJ, Hong YJ, Han KD, et al. Atopic dermatitis severity and risk for psoriasis: a nationwide population⁃based study［J］. Dermatology, 2024,240（2）:262⁃270. doi: 10.1159/000536143.
［11］	Cunliffe A, Gran S, Ali U, et al. Can atopic eczema and psoriasis coexist? A systematic review and meta⁃analysis［J］. Skin Health Dis, 2021,1（2）:e29. doi: 10.1002/ski2.29.
［12］	Barry K, Zancanaro P, Casseres R, et al. Concomitant atopic dermatitis and psoriasis ⁃ a retrospective review［J］. J Dermatolog Treat, 2021,32（7）:716⁃720. doi: 10.1080/09546634.2019.1702147.
［13］	Bozek A, Zajac M, Krupka M. Atopic dermatitis and psoriasis as overlapping syndromes［J］. Mediators Inflamm, 2020,2020:7527859. doi: 10.1155/2020/7527859.
［14］	Li M, Deng X, Wang J, et al. Clinical and pathological features of concomitant atopic dermatitis and psoriasis: a single⁃center retrospective study in China［J］. Dermatitis, 2024,35（5）:533⁃535. doi: 10.1089/derm.2023.0270.
［15］	Nakamura M, Lee K, Singh R, et al. Eczema as an adverse effect of anti⁃TNFα therapy in psoriasis and other Th1⁃mediated diseases: a review［J］. J Dermatolog Treat, 2017,28（3）:237⁃241. doi: 10.1080/09546634.2016.1230173.
［16］	Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases［J］. J Dermatol, 2018,45（6）:732⁃734. doi: 10.1111/1346⁃8138. 14295.
［17］	Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1440⁃1448. doi: 10.1111/jdv.16246.
［18］	Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti⁃interleukin 17 treatment of psoriasis: an emerging condition［J］. Br J Dermatol, 2019,181（3）:604⁃606. doi: 10.1111/bjd.17779.
［19］	Tang X, Li Q, Zhou Y, et al. Predictive factors of atopic⁃like dermatitis induced by IL⁃17A inhibitors in patients with psoriasis: a 2⁃year follow⁃up study［J］. J Eur Acad Dermatol Venereol, 2023,37（12）:2509⁃2516. doi: 10.1111/jdv.19394.
［20］	Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes［J］. Int J Mol Sci, 2022,23（10）:5518. doi: 10.3390/ijms23105518.
［21］	Aslan C, Göktay F, Mansur AT, et al. Clinicopathological consistency in skin disorders: a retrospective study of 3949 pathological reports［J］. J Am Acad Dermatol, 2012,66（3）:393⁃400. doi: 10.1016/j.jaad.2010.12.031.
［22］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［23］	Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA⁃C as the psoriasis susceptibility 1 gene［J］. Am J Hum Genet, 2006,78（5）:827⁃851. doi: 10.1086/503821.
［24］	Patrick GJ, Archer NK, Miller LS. Which way do we go? Complex interactions in atopic dermatitis pathogenesis［J］. J Invest Dermatol, 2021,141（2）:274⁃284. doi: 10.1016/j.jid.2020. 07.006.
［25］	Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL⁃13⁃dominant disease with greater molecular heterogeneity compared to psoriasis［J］. J Invest Dermatol, 2019,139（7）:1480⁃1489. doi: 10.1016/j.jid.2018.12.018.
［26］	Cookson WO, Ubhi B, Lawrence R, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci［J］. Nat Genet, 2001,27（4）:372⁃373. doi: 10.1038/86867.
［27］	Baurecht H, Hotze M, Brand S, et al. Genome⁃wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms［J］. Am J Hum Genet, 2015,96（1）:104⁃120. doi: 10.1016/j.ajhg.2014.12.004.
［28］	Hüffmeier U, Traupe H, Oji V, et al. Loss⁃of⁃function variants of the filaggrin gene are not major susceptibility factors for psoriasis vulgaris or psoriatic arthritis in German patients［J］. J Invest Dermatol, 2007,127（6）:1367⁃1370. doi: 10.1038/sj.jid.5700720.
［29］	Bergboer JG, Zeeuwen PL, Irvine AD, et al. Deletion of late cornified envelope 3B and 3C genes is not associated with atopic dermatitis［J］. J Invest Dermatol, 2010,130（8）:2057⁃2061. doi: 10.1038/jid.2010.88.
［30］	Chang YC, Wu WM, Chen CH, et al. Association between P478S polymorphism of the filaggrin gene and risk of psoriasis in a Chinese population in Taiwan［J］. Arch Dermatol Res, 2008,300（3）:133⁃137. doi: 10.1007/s00403⁃007⁃0821⁃2.
［31］	Hu Z, Xiong Z, Xu X, et al. Loss⁃of⁃function mutations in filaggrin gene associate with psoriasis vulgaris in Chinese population［J］. Hum Genet, 2012,131（7）:1269⁃1274. doi: 10. 1007/s00439⁃012⁃1155⁃5.
［32］	Nair RP, Duffin KC, Helms C, et al. Genome⁃wide scan reveals association of psoriasis with IL⁃23 and NF⁃kappaB pathways［J］. Nat Genet, 2009,41（2）:199⁃204. doi: 10.1038/ng.311.
［33］	Weidinger S, Novak N. Atopic dermatitis［J］. Lancet, 2016,387（10023）:1109⁃1122. doi: 10.1016/S0140⁃6736（15）00149⁃X.
［34］	Grolleau C, Calugareanu A, Demouche S, et al. IL⁃4/IL⁃13 inhibitors for atopic dermatitis induce psoriatic rash transcriptionally close to pustular psoriasis［J］. J Invest Dermatol, 2023,143（5）:711⁃721.e7. doi: 10.1016/j.jid.2022.10.015.
［35］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［36］	Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis［J］. J Invest Dermatol, 2008,128（11）:2625⁃2630. doi: 10.1038/jid.2008.111.
［37］	Suárez⁃Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis［J］. J Allergy Clin Immunol, 2013,132（2）:361⁃370. doi: 10.1016/j.jaci.2013.04.046.
［38］	Noda S, Suárez⁃Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization［J］. J Allergy Clin Immunol, 2015,136（5）:1254⁃1264. doi: 10.1016/j.jaci.2015.08.015.
［39］	Tsai YC, Tsai TF. Anti⁃interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness［J］. Ther Adv Musculoskelet Dis, 2017,9（11）:277⁃294. doi: 10.1177/1759720 X17735756.
［40］	Guttman⁃Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab （an IL⁃22 monoclonal antibody） in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double⁃blind, phase 2a trial［J］. J Am Acad Dermatol, 2018,78（5）:872⁃881.e6. doi: 10.1016/j.jaad.2018.01.016.
［41］	Krupka⁃Olek M, Bozek A, Drewienkowska M, et al. Immunological differences between atopic dermatitis, psoriasis, and their combination in adult patients［J］. Allergol Immunopathol （Madr）, 2022,50（4）:143⁃146. doi: 10.15586/aei.v50i4.557.
［42］	Kim JE, Lee J, Huh YJ, et al. Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis［J］. J Invest Dermatol, 2024,144（1）:43⁃52.e6. doi: 10.1016/j.jid.2023.06.194.
［43］	Müller S, Welchowski T, Schmid M, et al. Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis （the "Flip⁃Flop" phenomenon）［J］. Allergy, 2024,79（1）:164⁃173. doi: 10.1111/all.15921.
［44］	De D, Kanwar AJ, Handa S. Comparative efficacy of Hanifin and Rajka's criteria and the UK working party's diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India［J］. J Eur Acad Dermatol Venereol, 2006,20（7）:853⁃859. doi: 10.1111/j.1468⁃3083.2006.01664.x.
［45］	Burden⁃Teh E, Murphy R, Gran S, et al. Identifying the best predictive diagnostic criteria for psoriasis in children （< 18 years）: a UK multicentre case⁃control diagnostic accuracy study （DIPSOC study）［J］. Br J Dermatol, 2022,186（2）:341⁃351. doi: 10.1111/bjd.20689.
［46］	Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis［J］. JAAD Case Rep, 2019,5（11）:973⁃975. doi: 10.1016/j.jdcr.2019.09.005.
［47］	Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434. doi: 10.1111/bjd.20064.
［48］	Balestri R, Magnano M, Girardelli CR, et al. Long⁃term safety of combined biological therapy in a patient affected by arthropathic psoriasis and atopic dermatitis［J］. Dermatol Ther, 2020,33（4）:e13498. doi: 10.1111/dth.13498.
［49］	Barry K, Zancanaro P, Casseres R, et al. A retrospective review of dupilumab and psoriasis biologic combination therapy［J］. J Dermatolog Treat, 2021,32（4）:438⁃439. doi: 10.1080/09546634. 2019.1659481.
［50］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［51］	Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF⁃04965842 in patients with moderate⁃to⁃severe psoriasis: phaseⅡ, randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2018,179（1）:54⁃62. doi: 10.1111/bjd.16004.
［52］	Zhang L, Guo L, Wang L, et al. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis ⁃ a network meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1937⁃1946. doi: 10.1111/jdv.18263.
［53］	Patruno C, Fabbrocini G, De Lucia M, et al. Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib［J］. Dermatol Ther, 2022,35（11）:e15788. doi: 10.1111/dth.15788.
［54］	Ali K, Wu L, Qiu Y, et al. Case report: clinical and histopathological characteristics of psoriasiform erythema and de novo IL⁃17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab［J］. Front Med （Lausanne）, 2022,9:932766. doi: 10.3389/fmed.2022.932766.
［55］	Ferrucci SM, Buffon S, Marzano AV, et al. Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib［J］. Clin Exp Dermatol, 2022,47（5）:986⁃987. doi: 10.1111/ced.15104.
［56］	Kimura R, Sugita K, Yamamoto O. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab⁃induced eczema［J］. Eur J Dermatol, 2020,30（6）:732⁃734. doi: 10.1684/ejd.2020.3904.
［57］	Li Q, Li X, Li W, et al. Development of IL⁃17A inhibitor⁃induced atopic dermatitis⁃like rash in psoriasis patients: insights into immune shift［J］. Exp Dermatol, 2024,33（1）:e14958. doi: 10.1111/exd.14958.
［58］	Kapila S, Hong E, Fischer G. A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis⁃dermatitis［J］. Australas J Dermatol, 2012,53（2）:98⁃105. doi: 10.1111/j.1440⁃0960.2012. 00878.x.

[1]	Li Xiangqian, Zhang Jianzhong, Zhou Cheng. Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 646-649.
[2]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[3]	Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.
[4]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[5]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[6]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[7]	Wang Yujue, Li Qingyang, Wang Gang. Role of vascular endothelial cells in the pathogenesis of psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20250265-e20250265.
[8]	Ma Jing, Luan Chao, Chen Kun. Lipid metabolism-related proteins in psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220878-e20220878.
[9]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272.
[10]	Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268.
[11]	Huang Shudai, Zhou Xuyue, Zhang Jiaan, Chen Kun. Role of specialized pro-resolving mediators in psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240503-e0240503.
[12]	Jin Zhe, Gao Dong. Application and prospect of exosomes in infection and inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240148-e20240148.
[13]	Zhang Liangliang, Zhang Jiaan, Chen kun . Pathogenesis and treatment of scalp psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240001-e20240001.
[14]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[15]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2025, 0(2): 20230772-e20230772.

Psoriasis-atopic dermatitis overlap phenotype: immune dysregulation mechanisms and emerging clinical insights

PDF

Knowledge

Abstract

Cite this article

share this article

References ［58］

Related Articles 15

Metrics

Comments

Recommended 10